The biotech’s share price has now halved in 18 months, shredding more than $70 billion of shareholder wealth after the latest writedowns and operational struggles.
Business / Companies
Brisbane Times – Business
The biotech’s share price has now halved in 18 months, shredding more than $70 billion of shareholder wealth after the latest writedowns and operational struggles.
Business / Companies
Brisbane Times – Business